A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
Page DB, et al.
NPJ Breast Cancer
August 2023
Authors and Affiliates
David B Page 1, Joanna Pucilowska 2, Brie Chun 2, Isaac Kim 2, Katherine Sanchez 2, Nicole Moxon 2, Staci Mellinger 2, Yaping Wu 2, Yoshinobu Koguchi 2, Valerie Conrad 2, William L Redmond 2, Maritza Martel 2, Zhaoyu Sun 2, Mary B Campbell 2, Alison Conlin 2, Anupama Acheson 2, Reva Basho 3,4, Philomena McAndrew 3, Mary El-Masry 3, Dorothy Park 3, Laura Bennetts 2, Robert S Seitz 5, Tyler J Nielsen 5, Kimberly McGregor 5, Venkatesh Rajamanickam 2, Brady Bernard 2, Walter J Urba 2, Heather L McArthur 3,6;
1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. david.page2@providence.org.
2 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
3 Cedars Sinai Medical Center, Los Angeles, CA, USA.
4 Ellison Institute for Transformative Medicine, Los Angeles, CA, USA.
5 Oncocyte Corporation, Irving, CA, USA.
6 UT Southwestern Medical Center, Dallas, TX, USA.